BARCELONE, Espagne, 04 avr. 2024 (GLOBE NEWSWIRE) — La Barcelona Bridal Fashion Week (BBFW) 2024 s’annonce comme l’une des éditions les plus remarquables à ce jour avec la participation de plus de 37 marques qui se presseront sur le podium et plus de 400 entreprises présentes à ce salon professionnel. L’événement, organisé par Fira de Barcelona avec le soutien du Ministère catalan de l’Économie et du Travail, est devenu un point de rencontre privilégié pour les créateurs et les professionnels du monde de la mode nuptiale.
Affichant une augmentation de 14 % du nombre de marques présentes et un chiffre record de 80 % d’internationalité avec des entreprises originaires de plus de 35 pays, la BBFW 2024 qui se déroulera du 17 au 21 avril prochain, promet d’être une vitrine de l’excellence et de la créativité en matière de mode nuptiale.
Albasarí Caro, la directrice de la BBFW, souligne l’importance de cette édition qui « réunira les créateurs les plus prestigieux du secteur et fera, plus que jamais, de Barcelone, l’épicentre mondial des affaires et des tendances de cette industrie ».
En outre, le célèbre créateur de haute couture et de prêt-à-porter Giambattista Valli verra tous les projecteurs se braquer sur lui lors de la Barcelona Bridal Night avec la présentation de sa troisième « Love Collection » 2025, qui marquera le premier défilé de mode exclusivement nuptial de l’histoire de la maison.
Cet événement sera alors l’occasion de présenter également des marques de haute couture telles que Zuhair Murad, Elie Saab, Stephane Rolland ou Viktor&Rolf, ainsi que d’autres créateurs d’envergure internationale bien établis à l’instar de Jenny Packham, Tony Ward ou Ines Di Santo, rejoints pour la première fois dans cette édition par Georges Hobeika.
L’événement s’ouvrira dans la ville avec l’installation artistique Barcelona Goes Bridal! (en français : Barcelone se marie) un projet qui mettra en lumière le cycle de l’industrie de la mode nuptiale et sera l’occasion de présenter des robes de marques locales.
La BBFW 2024 ne se concentrera pas uniquement sur la mode et les tendances, mais s’intéressera aux affaires, grâce à un plan ambitieux destiné à attirer les principaux acheteurs du monde entier. Plus de 80 pays seront représentés, avec une forte présence des marchés clés tels que l’Europe, les États-Unis, le Japon, la Corée du Sud et l’Amérique latine.
La cérémonie des Barcelona Bridal & Fashion Awards viendra clore l’événement en récompensant le talent et la créativité des créateurs, ainsi que leur engagement en faveur de l’innovation, de la durabilité et de l’inclusion dans leurs collections.
La Barcelona Bridal Fashion Week édition 2024 promet d’être une célébration de l’excellence de la mode nuptiale, mettant l’accent sur l’internationalité, la créativité et les opportunités commerciales.
BARCELONA, Espanha, April 04, 2024 (GLOBE NEWSWIRE) — A Barcelona Bridal Fashion Week (BBFW) 2024 está pronta para se tornar uma das edições mais notáveis até hoje, com 37 grandes marcas na passarela e mais de 400 empresas participando da feira. O evento, organizado pela Fira de Barcelona e com apoio do Ministério de Negócios e Trabalho da Catalunha, tornou-se um ponto de encontro fundamental para designers e profissionais do mundo da moda nupcial.
Apresentando um aumento de 14% no número de marcas e um número recorde de 80% de internacionalidade (com empresas de mais de 35 países), a BBFW 2024 promete ser uma vitrine de excelência e criatividade em moda nupcial, entre os dias 17 e 21 de abril.
O diretor da BBFW, Albasarí Caro, destaca a importância de uma edição que “reunirá os designers mais prestigiados do setor e transformará Barcelona, mais do que nunca, no epicentro mundial dos negócios e das tendências do setor”.
Além disso, o renomado estilista de alta costura e itens “ready-to-wear” Giambattista Valli será a estrela da Noite Nupcial de Barcelona com a apresentação de sua terceira “Love Collection” 2025, a qual será também o primeiro desfile exclusivo para noivas na história da empresa.
O desfile também contará com as marcas de alta costura Zuhair Murad, Elie Saab, Stephane Rolland ou Viktor&Rolf, além de outros estilistas internacionais consagrados, como Jenny Packham, Tony Ward ou Ines Di Santo, com a presença, pela primeira vez nesta edição, de Georges Hobeika.
O evento se abrirá para a cidade com o Barcelona Goes Bridal!, uma instalação artística que representará o ciclo do setor de moda nupcial e exibirá vestidos de marcas locais.
A BBFW 2024 não se restringirá apenas à moda e às tendências, mas também aos negócios, com um plano ambicioso para atrair os principais clientes internacionais. Mais de 80 países estarão representados, contando com uma grande presença dos principais mercados, como Europa, EUA, Japão, Coreia do Sul e América Latina.
A cerimônia do Barcelona Bridal & Fashion Awards encerrará o evento, reconhecendo o talento e a criatividade dos estilistas, assim como seu compromisso com a inovação, a sustentabilidade e a inclusão em suas coleções.
A Barcelona Bridal Fashion Week 2024 se propõe a ser uma celebração da excelência em moda nupcial, com foco na internacionalidade, criatividade e oportunidades de negócios.
Para atendimento à imprensa, entre em contato com:
WASHINGTON, April 04, 2024 (GLOBE NEWSWIRE) — EB5 Capital is excited to announce that its Green House Gravity Apartments (JF39) project was approved by the United States Citizenship and Immigration Services (USCIS) on March 25, 2024, after pending for approximately 11 months. This Form I-956F approval confirms that USCIS has assessed and verified the compliance of the project and its related documents. Now that the project is approved by USCIS, investors who filed I-526E conditional green card petitions in this project can anticipate receiving individual petition approvals in the near future.
Green House Gravity Apartments (JF39) is the development of a Class A multifamily building with a high-end design centered around health and wellness. The project is in Columbus, Ohio, and when complete will contain 313 apartment units, 5,200 square feet of ground-floor retail, 324 secured garage spaces, a full fitness center, a pool and sauna, hot and cold plunge tubs, therapy rooms, and other onsite wellness services.
“We are pleased with this swift project approval from USCIS,” said Patrick Rainey, Senior Vice President of Investments at EB5 Capital. “The project began construction late last year when we started the EB-5 raise. We are happy that the raise is complete, and the project is approved, which are two significant milestones in the EB-5 process.”
Green House Gravity Apartments (JF39) represents Phase 3 of a master development plan and builds upon the momentum of Gravity Phases 1 and 2. Phase 1 consists of 234 units and was completed in 2019. Phase 2 consists of 325 units and opened in 2023. All three phases are adjacent to one another and are managed by Kaufman Development. EB5 Capital will continue to carefully track USCIS’ petition approvals in JF39 and attentively monitor the remainder of the construction process, keeping investors fully informed.
About EB5 Capital
EB5 Capital provides qualified foreign investors opportunities to invest in job-creating commercial real estate projects under the United States Immigrant Investor Program (EB-5 Visa Program). As one of the country’s oldest and most active Regional Center operators, the firm has raised more than one billion dollars of foreign capital across nearly 40 EB-5 projects. Headquartered in Washington, DC, EB5 Capital’s distinguished track record and leadership in the industry has attracted investors from over 75 countries. Please visit www.eb5capital.com for more information.
AI-Media Revolutionizes Captioning for DAZN with AI-Powered LEXI Tool Kit
AI-Media, a global leader in end-to-end captioning technology solutions, is excited to announce its newly established partnership with DAZN, the global sports entertainment streaming platform. Through this collaboration, AI-Media will deliver live and recorded multi language and translated captioning using various solutions from its AI-powered LEXI Tool Kit.
LONDON, April 04, 2024 (GLOBE NEWSWIRE) — AI-Media, a global leader in end-to-end captioning technology solutions, is excited to announce its newly established partnership with DAZN, the global sports entertainment streaming platform. Through this collaboration, AI-Media will deliver live and recorded multi language and translated captioning using various solutions from its AI-powered LEXI Tool Kit.
DAZN Group is one of the world’s fastest-growing sports media platforms, and this partnership marks a significant moment in their commitment to inclusivity and accessibility of their content. Leveraging AI-Media’s LEXI Tool Kit, DAZN will seamlessly integrate live captions across its extensive and diverse premium sports content, enriching the viewer experience for millions worldwide.
Key highlights of this partnership include:
Cutting-Edge Technology: LEXI 3.0, AI-Media’s latest automatic captioning solution, introduces innovative features such as speaker identification and AI-powered caption placement, ensuring accuracy exceeding 98%. LEXI’s advanced vocabulary caters to region-specific nuances, including challenging pronunciations and complex spellings, enhancing the quality of sport content captioning.
Complete End-to-End Solution: DAZN will utilize AI-Media’s Alta IP caption Encoder for LEXI Live captioning delivery. Alta offers a virtualized, API-powered software solution tailored for IP video environments, ensuring seamless integration.
Expanded Language Support: Initial rollout includes Spanish and English captions for EMEA and US markets, with plans for additional languages through LEXI Translate, encompassing French, German, Italian, Arabic, Japanese, and more. This supports DAZN’s global expansion strategy across its 120 channels, catering to diverse audiences worldwide.
Support for On-Demand FAST Channels: DAZN has implemented AI-Media’s LEXI Recorded solution for captioning pre-recorded content on their FAST (Free Ad-supported Streaming TV) Channels. LEXI Recorded, a newly launched solution in the LEXI Tool Kit, offers fast turnaround, highly accurate and low-cost captions – essential for high volume, time-sensitive captioning applications of recorded content such as this.
Cost-Effective Solution: Transitioning from costly human captioning services to AI-Media’s LEXI platform enables DAZN to deliver multi-language captions across multiple channels at the same cost as human delivery, enhancing accessibility while optimizing resources.
Mark Lovatt, General Manager of Global Strategic Accounts at AI-Media, expressed enthusiasm about the partnership: “With this new agreement, we’re excited to bring live and recorded multilingual captions to DAZN viewers using our LEXI Tool Kit solutions. Choosing AI-Media for LEXI automated captioning underscores the impact of Artificial Intelligence on the industry. As the top automatic captioning provider, we’re uniquely positioned to deliver high-quality captions for DAZN at a lower cost. This partnership marks a milestone in our global sports market expansion, and we’re thrilled to work with DAZN to make their content accessible to all viewers through our leading automated captions.”
James Pearce, SVP Broadcast & Streaming at DAZN, commended the partnership, saying, “DAZN is at the forefront of using technology to improve the enjoyment and viewing experience of fans. This partnership with AI-Media is another example of where DAZN uses best in class tech-based solutions to deliver the services and products that our customers want and expect. DAZN is all about putting customer choice at the centre of our offer, so we will be working hard to roll this out across all our services and looking forward to progressing this with AI-Media.”
As AI-Media continues to expand its footprint in the global sports market, this partnership exemplifies the dedication of both organizations to making content accessible to diverse audiences worldwide. Through innovative technologies and strategic collaborations such as this, AI-Media remains at the forefront of driving positive change in the media accessibility landscape.
About AI-Media:
Founded in Australia in 2003, AI-Media is a pioneering technology company specializing in innovative captioning workflow solutions. As a global leader, AI-Media provides high-quality AI-powered live and recorded captioning and translation technology and solutions to a diverse range of customers and markets worldwide. For the first time in February 2024, AI-Media was able to unveil groundbreaking data showcasing the superiority of its AI captioning product, LEXI, over traditional human workflows. This milestone further solidifies AI-Media’s position as the foremost AI technology leader in live and recorded captioning workflow solutions. With a commitment to utilising our deep industry experience and sophisticated AI technology to create solutions which streamline and simplify processes, AI-Media (ASX: AIM) empowers leading broadcasters, enterprises and government agencies globally to ensure seamless accessibility and inclusivity in their content.
For more information on AI-Media please visit AI-Media.tv
About DAZN:
DAZN is the home of European football, women’s football, boxing and MMA, and the NFL (excl. USA). DAZN is building the ultimate sports entertainment platform, based on premium sports rights, world-leading tech, and multi-platform distribution. DAZN believes that fans from across the globe should be able to watch, read, bet, play, share, socialise, buy tickets and merchandise, all in one place, with one account, one wallet and on one app.
For more information on DAZN, our products, people, and performance, visit dazngroup.com.
ATLANTA, April 04, 2024 (GLOBE NEWSWIRE) — Matmerize, Inc., a pioneering AI-based polymer informatics company, and CJ Biomaterials, a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, have joined forces to drive innovation in sustainable polymer solutions aimed at combating plastic pollution. In a recent collaboration with Matmerize, CJ Biomaterials successfully tested Matmerize’s cloud-based AI platform, PolymRize, to optimize bio-based polymers, ensuring they meet specific performance criteria across a wide range of applications.
Human life and plastic have become inseparable, but the environmental toll of plastic waste is undeniable. With more than 9 million tons of man-made plastic waste entering the ocean each year, the urgency to find sustainable alternatives has never been greater. In response to this challenge, CJ Biomaterials created PHACT, a groundbreaking 100% bio-based Polyhydroxyalkanoate (PHA) using an innovative fermentation process, that degrades naturally in soil and ocean environments, mitigating the harmful impact of plastic pollution on marine ecosystems.
One of the key challenges in materials development is the lengthy and resource-intensive process of characterizing core properties. By leveraging Matmerize’s custom model training and predictive analytics platform PolymRize, CJ Biomaterials was able to rapidly estimate the performance of newly designed materials, enabling quicker decision-making and reducing time and costs compared to traditional methods.
“The collaboration with CJ Biomaterials goes beyond R&D efforts, significantly impacting work efficiency and cost reduction by prioritizing experiments through expertise and machine learning capabilities. This commitment to innovation not only promotes sustainable practices but also secures a competitive advantage for CJ Biomaterials in the polymer and plastic industry.” – Dr. Chiho Kim, CTO, Matmerize, Inc
As Matmerize, Inc and CJ Biomaterials continue to push the boundaries of innovation in polymer development, the companies remain dedicated to driving positive environmental change and shaping a greener, sustainable future for generations to come.
About Matmerize: Matmerize, a spin-out from the Georgia Institute of Technology, is at the forefront of pioneering solutions that bridge the gap between AI and materials engineering. Matmerize’s PolymRize platform utilizes virtual screening and AI algorithms to identify the most optimal materials, empowering technologists to focus their experimental efforts on the most promising options with precision and efficiency. This approach significantly accelerates the materials engineering process saving valuable time and resources. PolymRize represents a paradigm shift in industry, propelling clients ahead of the competition and driving innovation at an unprecedented pace.
About CJ Biomaterials:
Headquartered in Woburn, MA, USA, CJ Biomaterials develops meaningful solutions that positively affect our planet, human health, and well-being by addressing the challenges posed by plastic waste. The company invents and manufactures biopolymers and bio-based chemicals as part of a long-term vision to create a more sustainable future, by enabling true circular solutions that replace many non-recyclable, non-reusable and fossil fuel-based plastics and chemicals. CJ Biomaterials is a global leader in the manufacture of polyhydroxyalkanoates (PHAs)–both polymers and associated basic chemicals. CJ Biomaterials, a business unit of CJ BIO, is part of CJ CheilJedang, a global lifestyle company with a vision to inspire a new life filled with health, happiness, and convenience.
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidate
Key takeaways:
Participants in Nigeria have been vaccinated with a Lassa fever vaccine candidate in the first Phase 2 clinical trial of any Lassa vaccine.
Lassa fever is a deadly hemorrhagic fever common to West Africa. No approved vaccine currently exists.
More than 600 participants in Ghana, Liberia, and Nigeria are expected to enroll in the IAVI-sponsored trial, funded by CEPI.
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor. The study (IAVI C105/PREVAIL15) is funded by CEPI, an innovative global partnership working to accelerate the development of vaccines against epidemic and pandemic threats.
Dr. Bolaji (left) is the Nigeria-based HJFMRI principal investigator for the IAVI C105 Lassa fever vaccine clinical trial at HJFMRI in Abuja, Nigeria
The trial in Nigeria has been designed in consultation with in-country partners, including the Nigeria Centre for Disease Control and Prevention and the Nigeria Lassa Vaccine Taskforce. HJF Medical Research International, Ltd/Gte (HJFMRI) has been conducting infectious diseases research in collaboration with HJF and the Walter Reed Army Institute of Research in Nigeria since 2014. In addition to Nigeria, and pending regulatory approval, IAVI expects to enroll additional participants at the Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences, University of Ghana, and the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL)1.
"Nigerian clinicians, scientists and community members are key leaders in this international collaboration, which will ensure that vaccine development incorporates local context, experience and perspectives while fostering sustainable in-country research capacity and partnerships," said Dr. Abdulwasiu Bolaji Tiamiyu, clinical research center director, HJFMRI, and principal investigator of IAVI C105 in Nigeria.
No approved vaccine currently exists for LASV, which causes an acute viral hemorrhagic illness called Lassa fever. Given its potential to cause a public health emergency of international concern, LASV is included in the World Health Organization R&D Blueprint of priority pathogens for which there is an urgent need for accelerated research and development (R&D) and countermeasures2. IAVI and members of the global Viral Hemorrhagic Fever Consortium have been collaborating since 2018 to accelerate clinical development of IAVI’s single-dose LASV vaccine candidate in studies supported and funded by CEPI and the European & Developing Countries Clinical Trials Partnership (EDCTP). Read more.
An estimated 5,000 people die each year from LASV, and about 300,000 people fall ill across West Africa annually – though the true disease burden is thought to be much higher. Nigeria, Liberia, Sierra Leone, and Guinea are most affected, but increasingly, neighboring countries are experiencing their own emerging outbreaks, with travelers occasionally carrying infections to other regions. Although most people who develop LASV have mild or no symptoms, approximately 20% will develop more serious symptoms including widespread bleeding and major organ failure. Approximately a third of those infected with LASV experience associated deafness, sometimes resulting in lifelong disability. Children under 10 years old, pregnant people, and health care workers are especially vulnerable to LASV infection.
"Continued outbreaks of Lassa fever and the emergence of Ebola Sudan in Uganda both underscore the need to have vaccines for known disease threats available for evaluation and use during outbreak situations – the overarching goal of IAVI’s emerging infectious disease program." said Swati Gupta, DrPH, MPH, vice president and head of emerging infectious diseases and epidemiology, IAVI. "IAVI C105 is an important step toward attaining eventual licensure of a Lassa fever vaccine, should IAVI’s vaccine candidate prove to have an acceptable safety profile and be efficacious. We are grateful to our funders, our clinical partners, and our consortium collaborators for their continued support of IAVI and commitment to a more secure world."
"Lassa fever has long been a threat to much of West Africa, and factors like climate change and population growth could exacerbate its transmission in coming decades," explains Dr. Richard Hatchett, CEO of CEPI. "The world urgently needs a Lassa vaccine for routine immunisation. The initiation of IAVI’s new Phase 2 trial – the most advanced Lassa vaccine trial to date – is an important milestone in public health and signals that better tools to manage and prevent outbreaks are coming. We look forward to continuing to collaborate with IAVI and regional partners to advance this promising vaccine as quickly as possible."
IAVI’s LASV vaccine candidate was well-tolerated and immunogenic among participants in both the U.S. and Liberian cohorts of IAVI’s Phase I LASV vaccine trial (IAVI C102). Robust immune responses appear to be sustained for up to one year after vaccination3. In the Phase 2 study, researchers will evaluate the vaccine candidate’s safety, tolerability, and immunogenicity at two different dosage levels in adults, including people living with HIV, as well as in adolescents and in children two years of age and older. Approximately 612 participants will be enrolled and followed for six months after vaccination to monitor their safety and immune responses. A subset of participants will be followed for an additional two years for extended safety and immunogenicity.
CEPI and IAVI are united in their commitment to global equitable access. Should the candidate be found to be safe and efficacious in clinical testing, IAVI is committed to making its Lassa vaccine affordable and accessible to all populations in need.
Harnessing a proven platform technology for global preparedness
IAVI’s LASV vaccine candidate uses the same recombinant vesicular stomatitis virus (rVSV) vector platform as ERVEBO®, Merck’s single-dose Zaire ebolavirus (ZEBOV) vaccine, which is licensed in North America, Europe, and 10 African countries. The rVSV platform has been used extensively in adults and children4.
IAVI’s goal is to develop and test rVSV-based vaccines against emerging infectious disease pathogens that pose epidemic threats as part of an overall preventive strategy which includes routine immunization as appropriate as well as stockpiles which can be rapidly deployed for larger outbreaks as needed. IAVI’s EID portfolio includes a Sudan ebolavirus vaccine candidate supported by BARDA; a Lassa fever vaccine candidate supported by CEPI and EDCTP; a Marburg virus vaccine candidate supported by BARDA and the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD); and an intranasal SARS-CoV-2 vaccine candidate supported by DOD DTRA and the Japan Ministry of Finance.
Much of the R&D on IAVI’s rVSV platform is performed at the IAVI Vaccine Design and Development Lab (DDL) in Brooklyn, New York. The DDL is one of the world’s leading viral vector vaccine R&D labs, known for innovation and generation of novel vaccine design concepts. Scientists with IAVI’s Human Immunology Laboratory (HIL) in London, U.K., are involved in processing participant samples and developing the analytical assays needed to evaluate IAVI C105 participants’ immune responses. They are also facilitating technology transfer of the assays to West African partner institutions.
IAVI’s LASV vaccine candidate was manufactured by Batavia Biosciences in Leiden, The Netherlands, a contract-development and manufacturing organization focused on delivering sustainable, low-cost manufacturing solutions in the field of infectious disease and cancer. Through its partnership with Batavia, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines.
Results from IAVI C105 are expected in 2025 and will be made available through open-access publications and via scientific meetings to ensure all can benefit from the research.
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.
CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About IAVI’s rVSV vaccine candidates
IAVI holds a nonexclusive license to the rVSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.
IAVI initially developed its rVSV vector for HIV vaccine candidates and has since expanded its use to the development of vaccines addressing emerging infectious diseases (Lassa Fever, Marburg, Sudan ebolavirus, and COVID-19).
Funders who have made the development of IAVI’s rVSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K. Foreign, Commonwealth & Development Office; the U.S. National Institutes of Health; and through the generous support of the American people from the United States Agency for International Development.
This project is funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract number 75A50121C00077.
1 PREVAIL is a Liberia-U.S. clinical research collaboration established in 2014 by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Ministry of Health in Liberia. In 2015, PREVAIL participated in a clinical trial (PREVAIL 1) of Merck’s now-licensed Ebola Zaire vaccine ERVEBO®, which uses the same recombinant vesicular stomatitis virus (rVSV) vector backbone as the candidates in IAVI’s emerging infectious diseases (EIDs) vaccine development portfolio, including the IAVI LASV vaccine candidate being evaluated in a Phase I clinical trial.
, to optimize bio-based polymers, ensuring they meet specific performance criteria across a wide range of applications.
